P769 Hypophosphatemia in patients with inflammatory bowel disease after intravenous iron infusion: One centre prospective study

Abstract Background Fatigue is a disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. We determined changes in fatigue status over time and identified predictors of incident or resolving fatigue. Methods This was a prospective study nested within the IBD Partners cohort. Participants prospectively completed the Multidimensional Fatigue Inventory and the Functional Assessment of Chronic Illness Therapy-Fatigue at baseline, 6 months, and 12 months. A Functional Assessment of Chronic Illness Therapy-Fatigue score ≤43 defined significant fatigue. Multivariable regression models using baseline covariates were used to identify risk factors for incident fatigue at 6 months and to predict the resolution of fatigue. Results A total of 2429 patients (1605 with Crohn disease, 824 with ulcerative colitis) completed a baseline assessment, and 1057 completed a second assessment at 6 months. Persistent fatigue (at baseline and at 6 months) was the most common pattern, affecting two-thirds (65.8%) of patients. One-sixth (15.7%) of patients had fatigue at 1 timepoint, whereas fewer than one-fifth (18.5%) of patients never reported fatigue. Among patients not fatigued at baseline, 26% developed fatigue at 6 months. The strongest predictor of incident fatigue was sleep disturbance at baseline (odds ratio, 2.91; 95% confidence interval, 1.48–5.72). In contrast, only 12.3% of those with fatigue at baseline had symptom resolution by month 6. Resolution was more likely in patients with a diagnosis of ulcerative colitis, quiescent disease, and an absence of significant psychological comorbidity. Conclusions Fatigue is common in patients with IBD. However, only a few fatigued patients experience symptom resolution at 6 or 12 months, suggesting the need for novel interventions to ameliorate its impact.

Download Full-text

A PROSPECTIVE STUDY OF THE PREVALENCE OF CYTOMEGALOVIRUS AND HUMAN HERPES 6 VIRUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

The American Journal of Gastroenterology ◽

10.1111/j.1572-0241.2003.08495.x ◽

2003 ◽

Vol 98 ◽

pp. S251

Author(s):

Paul A. Feldman ◽

Nevis Fregien ◽

Andrew Sable ◽

Alex Lenoue ◽

Solomon Singh ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Prospective Study ◽

Bowel Disease ◽

Human Herpes ◽

Inflammatory Bowel ◽

A Prospective Study

Download Full-text

Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study

Digestive Diseases and Sciences ◽

10.1007/s10620-018-5249-3 ◽

2018 ◽

Vol 63 (10) ◽

pp. 2815-2815

Author(s):

Dejan Micic ◽

Andres Yarur ◽

Alex Gonsalves ◽

Vijaya L. Rao ◽

Susan Broadaway ◽

...

Keyword(s):

Risk Factors ◽

Inflammatory Bowel Disease ◽

Clostridium Difficile ◽

Prospective Study ◽

Bowel Disease ◽

Inflammatory Bowel ◽

A Prospective Study

Download Full-text

A Behavioral Intervention Increases Medication Adherence in Inflammatory Bowel Disease (IBD) Patients: A Prospective Study

Gastroenterology ◽

10.1016/s0016-5085(17)30745-x ◽

2017 ◽

Vol 152 (5) ◽

pp. S123

Author(s):

Philip Oppong Twene ◽

Francis Farraye ◽

Tanvi A. Dhere ◽

Cameron B. Body ◽

Rachel Patzer ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Medication Adherence ◽

Prospective Study ◽

Behavioral Intervention ◽

Bowel Disease ◽

Inflammatory Bowel ◽

A Prospective Study

Download Full-text

P586 Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.707 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S538-S538

Author(s):

J Sleutjes ◽

A C de Vries ◽

J E Roeters van Lennep ◽

C J van der Woude

Keyword(s):

Inflammatory Bowel Disease ◽

Prospective Study ◽

Induction Therapy ◽

Bowel Disease ◽

Pearson Correlation ◽

Lipid Lowering ◽

Single Center ◽

Lipid Levels ◽

Drug Induced ◽

Inflammatory Bowel

Abstract Background Drug use in the treatment of inflammatory bowel disease (IBD) might negatively impact lipid levels. In this study, we assessed drug-induced changes in the lipid profile after IBD induction therapy. Methods In this single center, prospective study IBD patients aged ≥17 years who started systemic drug therapy (corticosteroids, thiopurines, methotrexate, infliximab, adalimumab, vedolizumab, ustekinumab and tofacitinib) for IBD were included. Exclusion criteria were pregnancy, history of liver transplantation and use of lipid lowering drugs. Data on cardiovascular risk profile, disease activity (HBI, SCCAI, CRP, FCP) and concomitant medication use were collected. To calculate mean lipid changes after induction therapy, nonfasting lipid levels (total cholesterol (TC), HDL-c, LDL-c, triglycerides (TG)) were measured before and 8–10 weeks after start of therapy. Pearson correlation test was performed to assess the association between lipid changes and CRP. Results A total of 183 patients (87 males (48%), median age 36 years (IQR 28–48), 128 Crohn’s disease (70%), 46 CU (3%), 9 IBD-U (7%)) were included. (Table 1) Fourty-nine patients were on concomitant steroids at baseline (31%). Relative increases in TC, HDL-c and LDL-c were significant after treatment with corticosteroids and tofacitinib (+9%, +17%, +8% and +19%, +29%, +24%, respectively) and decrease in TG after treatment with corticosteroids, thiopurines, infliximab, adalimumab, ustekinumab and tofacitinib (-9%, -14%, -10%, -8%, -11%, -8%, respectively). (Table 2, Figure 1) A significant inverse relationship was found between CRP and TC (R -.171), HDL-c (R -.202), LDL-c (R -.153) but not with TG. Conclusion Serum lipid levels increased most after start of corticosteroids and tofacitinib as compared to other drug therapies. Whether these changes are explained by the control of inflammation or by the mechanism of action of these agents remains undetermined.

Download Full-text